Literature DB >> 35003740

Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Rizka Asrini1, Maria Francisca Ham2,3, Asmarinah Asmarinah4, Agnes Stephanie Harahap2,3, Endang S R Hardjolukito2,3.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide. However, there is still limited information on the expression of programmed cell death ligand-1 (PD-L1), a type 1 transmembrane protein of immunoglobulin B7/CD28 in the DLBCL subtypes. The present study aimed to identify the expression of PD-L1 in germinal center B-cell-like (GCB) subtype and non-germinal center B-cell-like (non-GCB) subtype of DLBCL. A total of 40 patient samples (formalin-fixed paraffin-embedded tissues) consisting of 20 cases of GCB subtype and 20 cases of non-GCB subtype of DLBCL were examined. The PD-L1 protein expressions were evaluated by using immunohistochemical staining in the tumor cells. The results showed a statistically significant difference (P=0.003) between the expression of PD-L1 in the GCB subtype and the non-GCB subtype of DLBCL. PD-L1 expression in the tumor cells were observed in 13 cases (65%) of non-GCB subtype and in three cases (15%) of the GCB subtype of DLBCL. In conclusion, it was found that the expression of PD-L1 protein in the tumor cells of the non-GCB subtype of DLBCL was significantly higher as compared with the tumor cells of the GCB subtype of DLBCL.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  diffuse large B-cell lymphoma; immunohistochemistry; lymphoma; programmed cell death ligand-1

Year:  2021        PMID: 35003740      PMCID: PMC8739437          DOI: 10.3892/mco.2021.2474

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Authors:  Dohee Kwon; Sehui Kim; Pil-Jong Kim; Heounjeong Go; Soo Jeong Nam; Jin Ho Paik; Young A Kim; Tae Min Kim; Dae Seog Heo; Chul Woo Kim; Yoon Kyung Jeon
Journal:  Histopathology       Date:  2015-12-01       Impact factor: 5.087

Review 2.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Authors:  Junichi Kiyasu; Hiroaki Miyoshi; Akie Hirata; Fumiko Arakawa; Ayako Ichikawa; Daisuke Niino; Yasuo Sugita; Yuji Yufu; Ilseung Choi; Yasunobu Abe; Naokuni Uike; Koji Nagafuji; Takashi Okamura; Koichi Akashi; Ryoichi Takayanagi; Motoaki Shiratsuchi; Koichi Ohshima
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

Review 4.  Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.

Authors:  Mixue Xie; Xianbo Huang; Xiujin Ye; Wenbin Qian
Journal:  Int Immunopharmacol       Date:  2019-11-06       Impact factor: 4.932

5.  The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Authors:  Xia Fang; Bing Xiu; Zhizhang Yang; Weizhe Qiu; Long Zhang; Suxia Zhang; Yunjin Wu; Xuyou Zhu; Xue Chen; Suhong Xie; Xianghua Yi; Aibin Liang; Yu Zeng
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.

Authors:  Martina Ferrata; Arno Schad; Stefanie Zimmer; Thomas J Musholt; Katharina Bahr; Julian Kuenzel; Sven Becker; Erik Springer; Wilfried Roth; Matthias M Weber; Christian Fottner
Journal:  Front Oncol       Date:  2019-05-07       Impact factor: 6.244

7.  Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis.

Authors:  Aashka Sethi; Ankita Tandon; Harshi Mishra; Iqbal Singh
Journal:  J Oral Maxillofac Pathol       Date:  2019 May-Aug

8.  Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China.

Authors:  Yuankai Shi; Ying Han; Jianliang Yang; Peng Liu; Xiaohui He; Changgong Zhang; Shengyu Zhou; Liqiang Zhou; Yan Qin; Yongwen Song; Yueping Liu; Shulian Wang; Jing Jin; Lin Gui; Yan Sun
Journal:  Chin J Cancer Res       Date:  2019-02       Impact factor: 5.087

9.  Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.

Authors:  Li-Yang Hu; Xiao-Lu Xu; Hui-Lan Rao; Jie Chen; Ren-Chun Lai; Hui-Qiang Huang; Wen-Qi Jiang; Tong-Yu Lin; Zhong-Jun Xia; Qing-Qing Cai
Journal:  Chin J Cancer       Date:  2017-12-16

Review 10.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.

Authors:  Xianjie Jiang; Jie Wang; Xiangying Deng; Fang Xiong; Junshang Ge; Bo Xiang; Xu Wu; Jian Ma; Ming Zhou; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Can Guo; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2019-01-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.